Plupjeen Sa-Ngapong, Chawjiraphan Wireeya, Charoensiddhi Suvimol, Nitisinprasert Sunee, Nakphaichit Massalin
Department of Biotechnology, Faculty of Agro-Industry, Kasetsart University, 50 Ngam Wong Wan Rd, Lat Yao Chatuchak, Bangkok, 10900 Thailand.
Department of Food Science and Technology, Faculty of Agro-Industry, Kasetsart University, Chatuchak, Bangkok, 10900 Thailand.
3 Biotech. 2020 Jul;10(7):295. doi: 10.1007/s13205-020-02282-6. Epub 2020 Jun 8.
Probiotic is an alternative method to treat intestinal infection disease caused by antibiotic-resistant bacteria. In this study, KA-FF 1-4 demonstrated to have the potential to inhibit the growth of Vancomycin-resistant enterococci (VRE) by producing anti-microbial substance. In co-culture, KA-FF 1-4 (10 CFU/mL) inhibited the growth of VRE from 10-10 CFU/mL to zero after 6 h of exposure. However, in a gut model contained human gut microbiota, this anti-VRE activity of KA-FF 1-4 was reduced to only 3.59-6.12%. The unexpected difference in efficacy between the experimental models could be explained by the fact that the growth of KA-FF 1-4 was stable in the gut model. Leaving aside these limitations, we observed that adding KA-FF 1-4 into the human gut model containing VRE was able to enhance microbial richness and diversity. Specifically, a higher abundance of beneficial microbes from the group of spp. and . KA-FF 1-4 also enhanced the abundance of , , and and promoted the production of lactic acid in the gut model. However, these effects were not observed in the gut model without KA-FF 1-4. Even though this study could not demonstrate a significant anti-VRE effect of the KA-FF 1-4 in a gut model, our results still offer evidence that KA-FF 1-4 could positively modulate the gut microbiota by promoting the growth of beneficial microbes and their metabolite. KA-FF 1-4 has probiotic properties to fight against VRE infection, therefore further investigation in animal model is needed.
益生菌是治疗由抗生素耐药菌引起的肠道感染疾病的一种替代方法。在本研究中，KA-FF 1-4被证明有通过产生抗菌物质来抑制耐万古霉素肠球菌（VRE）生长的潜力。在共培养中，KA-FF 1-4（10⁶ CFU/mL）在暴露6小时后将VRE的生长从10⁸-10⁹ CFU/mL抑制至零。然而，在包含人类肠道微生物群的肠道模型中，KA-FF 1-4的这种抗VRE活性仅降至3.59-6.12%。实验模型之间疗效的意外差异可以用KA-FF 1-4在肠道模型中生长稳定这一事实来解释。抛开这些局限性，我们观察到将KA-FF 1-4添加到含有VRE的人类肠道模型中能够提高微生物的丰富度和多样性。具体而言，来自 spp. 和 组的有益微生物丰度更高。KA-FF 1-4还提高了 、 和 的丰度，并促进了肠道模型中乳酸的产生。然而，在没有KA-FF 1-4的肠道模型中未观察到这些效果。尽管本研究未能在肠道模型中证明KA-FF 1-4具有显著的抗VRE作用，但我们的结果仍然提供了证据，表明KA-FF 1-4可以通过促进有益微生物及其代谢产物的生长来积极调节肠道微生物群。KA-FF 1-4具有对抗VRE感染的益生菌特性，因此需要在动物模型中进一步研究。
